E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Public ClinicalTrials.gov record NCT05686226. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of T Cell Receptor Gene Therapy Targeting Human Papillomavirus ( HPV) 16 E7 for HPV-Associated Cancers
Study identification
- NCT ID
- NCT05686226
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Christian Hinrichs
- Other
- Enrollment
- 20 participants
Conditions and interventions
Conditions
- Anal Cancer
- Cervical Cancer
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- HPV Positive Rectal Squamous Cell Carcinoma
- HPV-Associated Vaginal Adenocarcinoma
- HPV-Related Adenocarcinoma
- HPV-Related Adenosquamous Carcinoma
- HPV-Related Anal Squamous Cell Carcinoma
- HPV-Related Carcinoma
- HPV-Related Cervical Carcinoma
- HPV-Related Endocervical Adenocarcinoma
- HPV-Related Malignancy
- HPV-Related Penile Squamous Cell Carcinoma
- HPV-Related Squamous Cell Carcinoma
- HPV-Related Vulvar Squamous Cell Carcinoma
- Metastatic Cancer
- Oropharynx Cancer
- Penile Cancer
- Throat Cancer
- Vaginal Cancer
- Vulva Cancer
Interventions
- Aldesleukin Drug
- E7 TCR-T cells Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 6, 2023
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
- Last update posted
- Feb 26, 2026
2023 – 2027
United States locations
- U.S. sites
- 3
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Institutes of Health Clinical Center | Bethesda | Maryland | 20892 | Recruiting |
| Rutgers Cancer Institute | New Brunswick | New Jersey | 08901 | Recruiting |
| RWJBarnabas Health - Robert Wood Johnson University Hospital | New Brunswick | New Jersey | 08901 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05686226, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 26, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05686226 live on ClinicalTrials.gov.